Amgen's Osteoporosis Drug Aims At Merck
Amgen (AMGN:Nasdaq - commentary - research) is gearing up to present additional clinical data on its experimental osteoporosis treatment AMG 162 -- one of the biotech giant's most promising late-stage drug candidates.